Anti-claudin 1 antibodies for use in the treatment of colorectal cancer

Patent metadata

Field	Value
Publication number	US-9931416-B2
Application number	US-201414909238-A
Country	US
Kind code	B2
Filing date	Jul 22, 2014
Priority date	Aug 2, 2013
Publication date	Apr 3, 2018
Grant date	Apr 3, 2018

Abstract

The present invention relates to anti-claudin 1 antibodies for use in the treatment of colorectal cancer. In particular, the present invention relates to a method of treating a colorectal cancer in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an anti-claudin 1 (CLDN1) antibody.

First claim

The invention claimed is:

1. A method of treating a colorectal cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-claudin 1 (CLDN1) antibody that comprises either (a) a heavy chain variable region as set forth in SEQ ID NO: 1 and a light chain variable region as set forth in SEQ ID NO: 5 or (b) a heavy chain variable region comprising the three complementarity determining regions (CDRs) of the heavy chain variable region set forth in SEQ ID NO: 1 and a light chain variable region comprising the three CDRs of the light chain variable region set forth in SEQ ID NO: 5.

2. The method of claim 1 wherein the antibody is selected from the group consisting of monoclonal antibodies, Fab antibodies, F(ab′)2 antibodies, TandAb dimer antibodies, Fv antibodies, scFv antibodies, dsFv antibodies, ds-scFv antibodies, Fd antibodies, minibodies, diabodies, bispecific antibody fragments, bibodies, tribodies, sc-diabodies, kappa(lamda) bodies (scFv-CL fusions); BiTE antibodies; DVD-Ig antibodies; SIP antibodies; SMIP antibodies; and DART antibodies.

3. The method of claim 1 wherein the antibody is a humanized antibody or a chimeric antibody.

4. The method of claim 1 wherein the anti-CLDN1 antibody comprises a heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO:6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region.

5. The method of claim 1 wherein the anti-CLDN1 antibody is an antibody drug conjugate.

6. The method of claim 5 wherein the anti-CLDN1 antibody is conjugated to a cytotoxic agent.

7. The method of claim 5 wherein the anti-CLDN1 antibody is conjugated to therapeutic agent selected from the group consisting of chemotherapeutic agents, prodrug converting enzymes, radioactive isotopes or compounds, and toxins.

8. The method of claim 6 wherein the cytotoxic agent is selected from the group consisting of antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents, anthracyclines, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinols, pre-forming compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisomerase inhibitors, and vinca alkaloids.

9. The method of claim 6 wherein the cytotoxic agent is selected from the group consisting of androgen, anthramycin (AMC), asparaginase, 5-azacytidine, azathioprine, bleomycin, busulfan, buthionine sulfoximine, camptothecin, carboplatin, carmustine, CC-1065, chlorambucil, cisplatin, colchicine, cyclophosphamide, cytarabine, cytidine arabinoside, cytochalasin B, dacarbazine, dactinomycin, daunorubicin, decarbazine, docetaxel, doxorubicin, an estrogen, 5-fluordeoxyuridine, etopside phosphate, 5-fluorouracil, gramicidin D, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, melphalan, 6-mercaptopurine, methotrexate, mithramycin, mitomycin C, mitoxantrone, nitroimidazole, paclitaxel, plicamycin, procarbizine, streptozotocin, tenoposid, 6-thioguanine, thioTEPA, topotecan, vinblastine, vincristine, and vinorelbine.

10. The method of claim 6 wherein the cytotoxic agent is selected from the group consisting of doxorubicin, paclitaxel, melphalan, vinca alkaloids, methotrexate, mitomycin C and etoposide.

11. The method of claim 6 wherein the cytotoxic agent is auristatin E or a derivative thereof.

12. The method of claim 5 wherein the anti-CLDN1 antibody is conjugated to a pro-drug converting enzyme.

13. The method of claim 12 wherein the pro-drug converting enzyme is selected from the group consisting of carboxypeptidase G2, beta-glucuronidase, penicillin-V-amidase, penicillin-G-amidase, beta-lactamase, beta-glucosidase, nitroreductase and carboxypeptidase A.

14. The method of claim 1 wherein the anti-CLDN1 antibody is used to induce antibody dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC).

15. The method of claim 1 wherein the anti-CLDN1 antibody is a bispecific antibody comprising one binding site for CLDN1 and a second binding side for an activating trigger molecule on an effector cell.

16. The method of claim 15 wherein the trigger molecule on an effector cell is selected from the group consisting of CD3 on T-cells, CD16 on natural killer cells, monocytes and macrophages, CD89 and CD64 on neutrophils and monocytes/macrophages, and DEC-205 on dendritic cells.

Assignees

• Inst Nat Sante Rech Med
• Univ De Montpellier 1
• Inst Regional Cancer Montpellier
• Univ Montpellier

Inventors

• Del Rio Marguerite
• Vezzio-Vie Nadia

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K16/3046

  Stomach, Intestines · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title